Highlights BioDelivery Sciences International, Inc.

Equities

BDSI

US09060J1060

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	22-05-05	CI
Collegium Pharmaceutical Completes Acquisition of BioDelivery Sciences	22-03-23	MT
Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International, Inc. for approximately $670 million.	22-03-20	CI
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	22-03-09	CI
BioDelivery Sciences International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-09	CI
Biodelivery Sciences International Announces ELYXYB Is Now Available in the U.S. for the Acute Treatment of Migraine	22-02-24	CI
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal; Shares Jump	22-02-14	MT
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal	22-02-14	MT
Collegium Pharmaceutical, Inc. entered into an agreement to acquire BioDelivery Sciences International, Inc. for approximately $580 million.	22-02-13	CI
BioDelivery Sciences International, Inc. Revises Earnings Guidance for the Full Year 2021	22-01-20	CI
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	21-11-03	CI
Earnings Flash (BDSI) BIODELIVERY SCIENCES INTERNATIONAL Posts Q3 Revenue $41.1M, vs. Street Est of $42M	21-11-03	MT
BioDelivery Sciences International, Inc. Provides Earnings Guidance for the Year 2021	21-11-03	CI
BioDelivery Sciences International : Appoints John Golubieski as Chief Financial Officer - Form 8-K	21-10-21	PU
BioDelivery Sciences International : Appoints John Golubieski as Chief Financial Officer	21-10-21	AQ
Dr Reddy Laboratories : Completes Sale of Rights for Migraine Treatment Drug in US, Canada	21-09-09	MT
BioDelivery Sciences International : Gets $24 Million Contract From Veteran Affairs	21-08-20	MT
Dr Reddy Laboratories : to Sell Rights for Migraine Treatment Drug in US, Canada for $15 Million	21-08-04	MT
BioDelivery Sciences International : to Buy US, Canadian Rights for Elyxyb Migraine Treatment From Dr. Reddy's	21-08-04	MT
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	21-08-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioDelivery Sciences International, Inc.

Equities

BDSI

US09060J1060

Highlights

Filters